Topline Data Expected in 2Q 2023 SEATTLE, Wash. and VANCOUVER, British Columbia, Feb. 7, 2023 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the final subject of the Company’s Phase 2 ORCA-V1 trial…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, Feb. 2, 2023 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will participate in one-on-one meetings during the 2023 SVB Securities Global Biopharma Conference. The conference is…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, Jan. 27, 2023 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has issued an inducement grant of stock options to a new employee. Achieve’s Board of…
/Read More
Topline Results Remain on Schedule to be Reported in the Second Quarter of 2023 SEATTLE, Wash. and VANCOUVER, British Columbia, January 9, 2023 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the final…
/Read More
SEATTLE, Wash and VANCOUVER, British Columbia, December 21, 2022 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,459,328 covering the mesylate…
/Read More